Refine by
Breast Cancer Treatment Articles & Analysis
15 articles found
Breast cancer is a type of cancer that begins in the cells of the breast. ...
Since the FDA approved the first oral small molecule targeted therapy for tumors-tamoxifen targeting the estrogen receptor (ER)-in 1977 for the treatment of breast cancer, small molecule drug development has typically focused on screening for high-affinity inhibitors. ...
In April 2020, it received accelerated approval from the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies. ...
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer – that is approximately 15% of all ...
Therefore, in the 2023 update of CSCO Guidelines for the Diagnosis and treatment of breast cancer, for patients with HER-2 positive breast cancer after neoadjuvant therapy, only trastuzumab was used in preoperative anti-HER-2 treatment, and non-pCR, T-DM1 evidence recommended for grade I was ...
The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment. ...
For example, a TPD drug developed by Arvinas has achieved proof-of-concept in clinical trials for the treatment of breast and prostate cancer. Researchers are also developing TPD drugs to treat other types of diseases. ...
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the ...
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. ...
The development of drug resistance is associated with multiple factors, including the level of PD-L1 expression in tumor cells, the tumor microenvironment, and the mutational load of genes that determine the cancer-immunecheck point. Recent macrogenome sequencing studies reveal that the gut microbiota is another key mediator of this tumor immune modulation site. It has been ...
The discovery of PI3K, a signaling pathway that promotes cancer growth, supports further research by scientists to investigate whether targeting MAPK4 in triple-negative breast cancer could improve cancer treatment. ...
The lengthy battle between people and varied bodily, chemical, and organic insults that trigger cell damage (e.g., merchandise of tissue harm, metabolites, and/or infections) have led to the evolution of assorted adaptive responses. These responses are triggered by recognition of damage-associated molecular patterns (DAMPs) and/or pathogen-associated molecular patterns (PAMPs), normally by cells ...
Radiation therapy choices vary for comprehensive breast cancer treatment. One such option, intraoperative radiation therapy (IORT) is employed in many centers around the country. ...
Head and neck cancer surgery presents a number of unique challenges, not only for the surgeon but for the radiation oncologist who will subsequently treat those patients. ...
Besides diabetes and insulin resistance, exposure to chlordane compounds have been linked to a variety of symptoms (headache, lethargy, upper respiratory infections), human cancers (prostate, breast, testicular, leukemia, lymphoma), and chronic diseases (allergies, anxiety, depression, Parkinson, Crohn’s disease). ...